

REMARKS

This is a full and timely response to the Office Action of February 7, 2007.

Reconsideration and allowance of the application and all presently pending claims are respectfully requested.

Upon entry of this Response, claims 1, 10, and 31-32 are pending in this application. Claims 2-9 and 11-30 have been canceled. Claims 1, 31, and 32 have been amended. The prior art made of record has been considered, but is not believed to affect the patentability of the presently pending claims. Applicants believe that no new matter has been added by the amendments and that a new search is not necessary.

Applicants thank the Examiner for indicating that the claims as amended appear to be in condition for allowance during our phone conference on March 28.

CLAIMS

Claim 1

Claim 1 is rejected under 35 U.S.C. §102(e) as purportedly being anticipated by Patel et al. (U.S. Patent Application Publication 2004/0145088 ("Patel I")) and Patel et al. (U.S. Patent Application Publication 2004/0207123 ("Patel II")).

Applicants traverse each of the §102 rejections in the Office Action and submit that the rejection of claim 1 under 35 U.S.C. §102 (e) in view of each Patel I and Patel II should be withdrawn because none of the references, individually or in combination, disclose, teach, or suggest each and every feature of claim 1 above. In this regard, Patel I and Patel II do not, individually or in combination, disclose, teach, or suggest that "the norbornene based build material is selected from the group consisting of: functionalized norbornene compounds, dicyclopentadiene, and combinations thereof, wherein functionalized norbornene compounds does not include functionalized hetero-norbornene compounds or hetero-norbornene

compounds” as recited in claim 1. Applicants are intending to claim functionalized norbornene compounds, dicyclopentadiene, and combinations thereof as the norbornene based build material recited in claim 1. Applicants are not intending to claim functionalized hetero-norbornene compounds or hetero-norbornene compounds as the norbornene based build material recited in claim 1. Thus, claim 1 is in condition for allowance.

Applicants respectfully request that the Examiner call the undersigned attorney to resolve this misunderstanding.

Claims 10

Applicants traverse each of the §102 rejections in the Office Action. Applicants respectfully submit that pending dependent claim 10 includes every feature of independent claim 1 and that Patel I and Patel II each fail to disclose, teach, or suggest, individually or in combination, at least the features of claim 1 highlighted hereinabove. Thus, pending dependent claim 10 is also allowable over the prior art of record. In re Fine, 5 U.S.P.Q.2d 1596, 1600 (Fed. Cir. 1988).

Claim 31

Claim 31 is rejected under 35 U.S.C. §102(e) as purportedly being anticipated by Patel et al. (U.S. Patent Application Publication 2004/0145088 (“Patel I”)) and Patel et al. (U.S. Patent Application Publication 2004/0207123 (“Patel II”)).

Applicants traverse each of the §102 rejections in the Office Action and submit that the rejection of claim 31 under 35 U.S.C. §102 (e) in view of each Patel I and Patel II should be withdrawn because none of the references, individually or in combination, disclose, teach, or suggest each and every feature of claim 31 above. In this regard, Patel I and Patel II do not, individually or in combination, disclose, teach, or suggest that “the norbornene based build

material is selected from the group consisting of: functionalized norbornene compounds, dicyclopentadiene, and combinations thereof, wherein functionalized norbornene compounds does not include functionalized hetero-norbornene compounds or hetero-norbornene compounds” as recited in claim 31. Applicants are intending to claim functionalized norbornene compounds, dicyclopentadiene, and combinations thereof as the norbornene based build material recited in claim 31. Applicants are not intending to claim functionalized hetero-norbornene compounds or hetero-norbornene compounds as the norbornene based build material recited in claim 31. Thus, claim 31 is in condition for allowance.

Applicants respectfully request that the Examiner call the undersigned attorney to resolve this misunderstanding.

Claim 32

Claim 32 is rejected under 35 U.S.C. §103(a) as purportedly being unpatentable by Patel et al. (U.S. Patent Application Publication 2004/0145088 (“Patel I”)) or Patel et al. (U.S. Patent Application Publication 2004/0207123 (“Patel II”)).

Applicants traverse each of the §103 rejections in the Office Action and submit that the rejection of claim 32 under 35 U.S.C. §103 (a) in view of each Patel I and Patel II should be withdrawn because none of the references, individually or in combination, disclose, teach, or suggest each and every feature of claim 32 above. In this regard, Patel I and Patel II do not, individually or in combination, disclose, teach, or suggest that “the norbornene based build material is selected from the group consisting of: functionalized norbornene compounds, dicyclopentadiene, and combinations thereof, wherein functionalized norbornene compounds does not include functionalized hetero-norbornene compounds or hetero-norbornene compounds” as recited in claim 32. Applicants are intending to claim functionalized norbornene compounds, dicyclopentadiene, and combinations thereof as the norbornene

based build material recited in claim 32. Applicants are not intending to claim functionalized hetero-norbornene compounds or hetero-norbornene compounds as the norbornene based build material recited in claim 32. Thus, claim 32 is in condition for allowance.

Applicants respectfully request that the Examiner call the undersigned attorney to resolve this misunderstanding.


Conclusion

In light of the foregoing amendments and for at least the reasons set forth above, Applicants respectfully submit that all objections and/or rejections have been traversed, rendered moot, and/or accommodated. Favorable reconsideration and allowance of the present application and all pending claims are hereby courteously requested.

In addition, any other statements in the Office Action that are not explicitly addressed herein are not intended to be admitted. In addition, any and all findings of inherency are traversed as not having been shown to be necessarily present. Furthermore, any and all findings of well-known art and official notice, or statements interpreted similarly, should not be considered well known since the Office Action does not include specific factual findings predicated on sound technical and scientific reasoning to support such conclusions.

If, in the opinion of the Examiner, a telephonic conference would expedite the examination of this matter, the Examiner is invited to call the undersigned attorney at (770) 933-9500.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'CBL', is written over a horizontal line.

Christopher B. Linder, Reg. No. 47,751

**THOMAS, KAYDEN,
HORSTEMEYER & RISLEY, L.L.P.**
Suite 1750
100 Galleria Parkway N.W.
Atlanta, Georgia 30339
(770) 933-9500



CERTIFICATE OF MAILING

I hereby certify that the below listed items are being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

on 4/2/07

Sara Rogers
Sara A. Rogers

In Re Application of:

Oliver, et al.

Serial No.: 10/642,971

Filed: August 18, 2003

Confirmation No.: 3388

Group Art Unit: 1732

Examiner: Leo B. Tentoni

Docket No. HP: 200309784-1
TKHR: 050834-1050

For: SYSTEMS AND METHODS FOR USING NORBORNENE BASED CURABLE MATERIALS

The following is a list of documents enclosed:

Return Postcard
Amendment
Amendment Transmittal Sheet